La NaciónIndependent🔒Center3 hr. agoArgentina's National Administration of Medicines, Foods and Medical Technology (Anmat) has approved the over-the-counter sale of ten groups of medications that previously required a prescription. This change was implemented through Resolution 4714/2026 and applies to all registered medicinal products meeting the specified compositions and formats outlined in the regulation. The affected drugs will no longer qualify for discounts offered by health insurance providers. Among the active ingredients included are trimebutine maleate, levocetirizine dihydrochloride, and fexofenadine hydrochloride, available in various forms such as tablets, capsules, and oral solutions. These medications had been sold under prescription for at least five years without reports of serious adverse effects. Anmat evaluated data from the National Pharmacovigilance System and the World Health Organization’s global database of adverse reactions, concluding that these drugs carry a low risk of severe side effects. Regulatory agencies in Europe, Spain, France, the United States, Brazil, and Colombia also approve their sale without a prescription.
Bias read (Center): The article presents a factual update on regulatory changes made by Anmat regarding medication sales. It provides technical details about the drugs involved, the evaluation process, and the criteria used to determine the change in classification. There is no evident ideological framing, loaded langa
PerfilIndependentCenter4 hr. agoThe Argentine National Administration of Medicines, Foods and Medical Technology (ANMAT) has authorized the over-the-counter sale of ten groups of medications that previously required a prescription. This decision was formalized through Resolution 4714/2026, published on July 28, 2026, in the Official Gazette, and will take effect the following day. The authorization applies to all medical specialties registered in the Registry of Medical Specialties (REM) containing specific active ingredients, concentrations, associations, and pharmaceutical forms outlined in the regulation. However, this does not automatically extend to all commercial presentations of these medications. Among the products included are trimebutine maleate, levocetirizine dihydrochloride, fexofenadine hydrochloride, dimenhydrinate, and carboxymethylcysteine in liquid form. Additionally, certain eye drops and topical products such as aluminum chloride hexahydrate and ivermectin-based lotions were approved for sale without a prescription.
Bias read (Center): The article provides a factual report on regulatory changes by ANMAT regarding medication sales. It presents the new regulations neutrally, listing the affected drugs and their conditions without apparent ideological framing or biased language. There is no evident emphasis on political implications,
AR
